Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
| Autor: | Maja J.A. de Jonge, James P. O'Brien, Erik A.C. Wiemer, Yoshiharu Mizui, Ferry A.L.M. Eskens, José Baselga, M. J. Carreras, Adelaida Piera, Francisco Javier Ramos, Josep Tabernero, Herman Burger |
|---|---|
| Přispěvatelé: | Medical Oncology |
| Rok vydání: | 2013 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Maximum Tolerated Dose Nausea Apoptosis Pharmacology Gastroenterology Drug Administration Schedule Article Bolus (medicine) Pharmacokinetics SDG 3 - Good Health and Well-being Neoplasms Internal medicine medicine Humans RNA Messenger Aged Volume of distribution Antibiotics Antineoplastic business.industry Standard treatment Middle Aged Treatment Outcome Oncology Tolerability Pharmacodynamics Leukocytes Mononuclear Spliceosomes Vomiting Epoxy Compounds M Phase Cell Cycle Checkpoints Female Macrolides medicine.symptom business |
| Zdroj: | Clinical Cancer Research, 19(22), 6296-6304. American Association for Cancer Research Inc. |
| ISSN: | 1078-0432 |
| Popis: | Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule. Experimental Design: Patients with solid tumors refractory to standard therapies or with no standard treatment available were enrolled. Dose levels of 0.6 to 4.5 mg/m2 were explored. Results: Forty patients [24M/16F, median age 61 years (45–79)] were enrolled. At 4.5 mg/m2, dose-limiting toxicity (DLT) consisted of grade 3 diarrhea, nausea, and vomiting and grade 4 diarrhea, respectively, in two patients. At 4.0 mg/m2, DLT (grade 3 nausea, vomiting, and abdominal cramps) was observed in one patient. Frequently occurring side effects were mainly gastrointestinal. After drug discontinuation at 4.0 mg/m2, one patient experienced reversible grade 4 blurred vision. The maximum tolerated dose (MTD) is 4.0 mg/m2. No complete or partial responses during treatment were observed; one patient at 4.0 mg/m2 had a confirmed partial response after drug discontinuation. Pharmacokinetic analysis revealed a large volume of distribution, high systemic clearance, and a plasma elimination half-life of 5.3 to 15.1 hours. Overall drug exposure increased in a dose-dependent manner. At the MTD, mRNA levels of selected target genes monitored in peripheral blood mononuclear cells showed a reversible 15- to 25-fold decrease, whereas unspliced pre-mRNA levels of DNAJB1 and EIF4A1 showed a reversible 10- to 25-fold increase. Conclusion: The MTD for E7107 using this schedule is 4.0 mg/m2. Pharmacokinetics is dose-dependent and reproducible within patients. Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107. Clin Cancer Res; 19(22); 6296–304. ©2013 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|